ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant

In brief

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?

Key facts

Study ID
NCT07284667
Run by
ACADIA Pharmaceuticals Inc.
People needed
153
Starts
2025-11-14
Expected to finish
2027-09-01
Last updated by the study team
2026-08-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.